Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Current Cardiology Reports

Bioresorbable Scaffolds: Ready for a Rematch?

  • 01-12-2026
  • Thrombosis
  • Interventional Cardiology (SR Bailey and T Helmy, Section Editors)
Published in:
Authors
Oludamilola Akinmolayemi
Alexander Levy
Swagata Patnaik
Gregg W. Stone
Solomon W. Bienstock
Published in
Current Cardiology Reports | Issue 1/2026

Abstract

Purpose of Review

The bioresorbable vascular scaffold (BVS) is a promising technology with clear theoretical benefits. Large randomized controlled trials (RCTs) of the early generation of this technology, however, demonstrated issues translating these benefits from the abstract into the clinical realm. This review covers the outcomes beginning with the first-generation scaffolds and provides updates on advances made with newer technologies and evolved approaches to platform delivery.

Recent Findings

Pooled individual patient data from the ABSORB studies with 5-year follow-up was published in early 2025, showing higher event rates in the BVS group driven by events in the first three years of follow-up. Events after three years were the same or lower compared to traditional metallic drug-eluting stents (DES).

Summary

BVS technology is not yet ready for clinical primetime. However, there is need for improved scaffold technology and new BVS will again need to be tested against metallic DES in large-scale RCTs with long-term follow-up.
Title
Bioresorbable Scaffolds: Ready for a Rematch?
Authors
Oludamilola Akinmolayemi
Alexander Levy
Swagata Patnaik
Gregg W. Stone
Solomon W. Bienstock
Publication date
01-12-2026
Publisher
Springer US
Keyword
Thrombosis
Published in
Current Cardiology Reports / Issue 1/2026
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-025-02291-y
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 1/2026

Catheter-Based Valvular and Structural Interventions in Cancer Patients

Race and Patient-Physician Communication on Blood Pressure Management: Helping Improve Care

  • Open Access
  • Hypertension
  • Diversity and Health Equity in Cardiology (AE Johnson, Section Editor)

Assessment of Right Ventricular Function Prior to Transcatheter Tricuspid Valve Interventions

  • CSF Drainage
  • Structural Heart Disease (S Vakamudi, Section Editor)

Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations

  • Statins
  • Lipid Abnormalities and Cardiovascular Prevention (NJ Pagidipati, Section Editor)

Echocardiography in Athletes: the Ever-Evolving Assessment of Physiology Versus Pathology

  • Open Access
  • CSF Drainage
  • Echocardiography (JM Gardin and AH Waller, Section Editors)

Mesenchymal Stem Cell Based-Regenerative Therapy in Atherosclerosis: an Updated Review

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME